# PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

> **NCT02819752** · PHASE1 · TERMINATED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 3 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02819752
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-12
- **Primary completion:** 2019-11-28
- **Final completion:** 2019-11-28
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** funding pulled
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819752, "PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02819752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*